Blue Owl Capital Holdings LP Has $3.84 Million Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)

Blue Owl Capital Holdings LP grew its position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 97.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 242,633 shares of the company's stock after buying an additional 120,000 shares during the period. Keros Therapeutics accounts for approximately 0.9% of Blue Owl Capital Holdings LP's investment portfolio, making the stock its 24th largest holding. Blue Owl Capital Holdings LP owned approximately 0.60% of Keros Therapeutics worth $3,841,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in KROS. Vanguard Group Inc. increased its position in Keros Therapeutics by 5.4% in the fourth quarter. Vanguard Group Inc. now owns 1,957,109 shares of the company's stock worth $30,981,000 after purchasing an additional 100,691 shares during the period. Geode Capital Management LLC raised its stake in shares of Keros Therapeutics by 5.5% during the fourth quarter. Geode Capital Management LLC now owns 765,436 shares of the company's stock worth $12,120,000 after buying an additional 39,815 shares during the last quarter. American Century Companies Inc. lifted its holdings in Keros Therapeutics by 10.5% in the fourth quarter. American Century Companies Inc. now owns 328,920 shares of the company's stock valued at $5,207,000 after buying an additional 31,251 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Keros Therapeutics by 7.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 279,682 shares of the company's stock valued at $4,427,000 after acquiring an additional 19,562 shares during the last quarter. Finally, Emerald Advisers LLC grew its holdings in Keros Therapeutics by 57.3% during the 4th quarter. Emerald Advisers LLC now owns 244,633 shares of the company's stock worth $3,873,000 after acquiring an additional 89,088 shares during the period. 71.56% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on KROS. Piper Sandler cut their price target on Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating on the stock in a research note on Friday, January 17th. Truist Financial cut their target price on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a research note on Wednesday, April 9th. Oppenheimer decreased their target price on Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating for the company in a research report on Thursday, January 16th. HC Wainwright reiterated a "buy" rating and issued a $40.00 price target on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Finally, Wells Fargo & Company reduced their price objective on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, February 27th. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $40.33.

Insider Activity

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the stock in a transaction dated Wednesday, April 9th. The shares were bought at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the acquisition, the insider now directly owns 4,392,737 shares of the company's stock, valued at approximately $44,498,425.81. This trade represents a 27.01 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 22.90% of the company's stock.

Keros Therapeutics Stock Performance

KROS stock traded down $0.21 during mid-day trading on Friday, hitting $14.21. 1,003,205 shares of the company were exchanged, compared to its average volume of 801,264. Keros Therapeutics, Inc. has a 1-year low of $9.12 and a 1-year high of $72.37. The firm's 50 day simple moving average is $11.56 and its 200 day simple moving average is $27.66. The firm has a market cap of $576.39 million, a P/E ratio of -2.73 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, topping analysts' consensus estimates of ($1.36) by $0.22. The business had revenue of $3.04 million for the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. On average, equities research analysts predict that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.